Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer

Gastric Cancer

Volumn 19, Issue 2, 2016, Pages 412-420

  Di Bartolomeo, Maria ^a   Pietrantonio, Filippo ^a   Pellegrinelli, Alessandro ^a   Martinetti, Antonia ^a   Mariani, Luigi ^a   Daidone, Maria Grazia ^a   Bajetta, Emilio ^b   Pelosi, Giuseppe ^a   de Braud, Filippo ^a   Floriani, Irene ^c   Miceli, Rosalba ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Medical Oncology Unit   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Adjuvant chemotherapy; Biomarker; Gastric cancer; Osteopontin; Prognosis

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CISPLATIN; CYCLOOXYGENASE 2; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OSTEOPONTIN; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; SPP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GASTRECTOMY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; RADICAL RESECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RELAPSE; STOMACH CANCER; TRANSLATIONAL RESEARCH; TUMOR RECURRENCE; CLINICAL TRIAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STOMACH NEOPLASMS;

AGED; BETA CATENIN; BIOMARKERS, TUMOR; CADHERINS; CYCLOOXYGENASE 2; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84927555675     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-015-0495-y     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
2. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable GC: a meta-analysis. JAMA. 2010;303:1729–37.
3. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
5. Miceli R, Tomasello G, Bregni G, Di Bartolomeo M, Pietrantonio F. Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. World J Gastroenterol. 2014;20:4516–25 review.
6. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17:2693–701.
7. Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, et al. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res. 2013;33:1257–66.
8. Pignatelli M, Vessey CJ. Adhension molecules: novel molecular tools in tumor pathology. Hum Pathol. 1994;25:849–56.
9. Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol. 2012;18:3923–30.
10. Song G, Ouyang G, Mao Y, Ming Y, Bao S, Hu T. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med. 2009;13:1706–18.
11. Tang H, Wang J, Bai F, Zhai H, Gao J, Hong L, et al. Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest. 2008;26:60–7.
12. Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014;25:1373–8.
13. Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of GC: a meta-analysis. J Natl Cancer Inst. 2013;105:1600–7.
14. Jung H, Lee HH, Song KY, Jeon HM, Park CH. Validation of the seventh edition of the American Joint Committee on Cancer TNM staging system for gastric cancer. Cancer. 2011;117:2371–8.
15. Ito T, Hashimoto Y, Tanaka E, Kan T, Tsunoda S, Sato F, et al. An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res. 2006;12:1308–16.
16. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology. 1997;112:46–54.
17. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395–403.
18. Miceli R, Lusa L, Mariani L. Revising a prognostic index developed for classification purposes: an application to GC data. J Appl Stat. 2004;31:817–30.
19. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21:3647–50.
20. Dai N, Bao Q, Lu A, Li J. Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology. 2007;72:89–96.
21. Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol. 2007;14:3419–27.
22. Imano M, Satou T, Itoh T, Sakai K, Ishimaru E, Yasuda A, et al. Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg. 2009;13:1577–82.
23. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56:782–9.
24. Chen X, Meng T, Hao B, Zhang Z, Zhang G. Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer. 2012;12:477.
25. Wang ZM, Cui YH, Li W, Chen SY, Liu TS. Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells. Oncol Rep. 2011;25:997.
26. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points—the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7:309–17.